# YDES (YD Bio Limited) - SEC EDGAR Financial Statements

> YD Bio Limited reported $597K in revenue and a net loss of $8.31M for the fiscal year ended December 31, 2025 (up 16.9% year over year), with a 28.1% gross margin and a -883.3% operating margin.

- Canonical: https://convexityos.com/fundamentals/YDES
- Markdown: https://convexityos.com/fundamentals/YDES.md
- SEC CIK: 0002011674
- Reporting currency: USD
- Latest filing period: December 31, 2025
- Last synced: Nov 20, 2026, 05:37 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002011674&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $597K | +16.9% YoY |
| Operating Income | FY 2025 | -$5.27M | -883.3% margin |
| Net Income | FY 2025 | -$8.31M | -1392.6% net margin |
| Diluted EPS | FY 2025 | -$0.12 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$8.04M | -1346.6% FCF margin |
| Cash & ST Investments | Dec 31, 2025 | $6.01M | Total debt: $14K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Revenue** | $597K | $510K | $350K |
| Cost of Revenue | $429K | $355K | $197K |
| **Gross Profit** | $167K | $155K | $153K |
| Research & Development | $1.60M | $491K | -- |
| Selling, General & Admin | $3.83M | $1.13M | $161K |
| Total Operating Expenses | $5.44M | $1.62M | $163K |
| **Operating Income** | -$5.27M | -$1.46M | -$9.8K |
| **EBITDA** | -$5.06M | -$1.36M | -$7.4K |
| Interest Income | $80K | $12K | $290 |
| Interest Expense | -- | $772 | $2.1K |
| Income Before Tax | -$8.31M | -$1.39M | $18K |
| Income Tax Expense | -$1.5K | $25K | $4.1K |
| **Net Income** | -$8.31M | -$1.41M | $14K |
| Basic EPS | -$0.12 | -$0.02 | $0.00 |
| **Diluted EPS** | -$0.12 | -$0.02 | $0.00 |
| Basic Shares Outstanding | 66.7M | 64.7M | 64.7M |
| Diluted Shares Outstanding | 66.7M | 64.7M | 64.7M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $6.01M | $3.13M |
| **Cash & Short-Term Investments** | $6.01M | $3.13M |
| Accounts Receivable, Net | $167K | $87K |
| Inventory | $1.88M | $37K |
| **Total Current Assets** | $9.67M | $3.47M |
| Property, Plant & Equipment, Net | $59K | $64K |
| Intangible Assets | $2.61M | $2.68M |
| **Total Non-Current Assets** | $4.11M | $3.40M |
| **Total Assets** | $13.78M | $6.86M |
| Accounts Payable | $413K | $27K |
| Deferred Revenue (Current) | $30K | $28K |
| **Total Current Liabilities** | $1.64M | $263K |
| Long-Term Debt | $6.8K | -- |
| **Total Non-Current Liabilities** | $14.99M | $11K |
| **Total Liabilities** | $16.64M | $274K |
| **Total Debt (incl. Leases)** | $14K | $22K |
| Common Stock | $7.1K | $6.5K |
| Retained Earnings | -$10.24M | -$1.93M |
| Accumulated Other Comp. Income | $214K | $45K |
| **Total Stockholders' Equity** | -$2.86M | $6.59M |
| Total Equity | -$2.86M | $6.59M |

### Balance Sheet (Quarterly)

| Line Item | Dec 2025 | Dec 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $6.01M | $3.13M |
| **Cash & Short-Term Investments** | $6.01M | $3.13M |
| Accounts Receivable, Net | $167K | $87K |
| Inventory | $1.88M | $37K |
| **Total Current Assets** | $9.67M | $3.47M |
| Property, Plant & Equipment, Net | $59K | $64K |
| Intangible Assets | $2.61M | $2.68M |
| **Total Non-Current Assets** | $4.11M | $3.40M |
| **Total Assets** | $13.78M | $6.86M |
| Accounts Payable | $413K | $27K |
| Deferred Revenue (Current) | $30K | $28K |
| **Total Current Liabilities** | $1.64M | $263K |
| Long-Term Debt | $6.8K | -- |
| **Total Non-Current Liabilities** | $14.99M | $11K |
| **Total Liabilities** | $16.64M | $274K |
| **Total Debt (incl. Leases)** | $14K | $22K |
| Common Stock | $7.1K | $6.5K |
| Retained Earnings | -$10.24M | -$1.93M |
| Accumulated Other Comp. Income | $214K | $45K |
| **Total Stockholders' Equity** | -$2.86M | $6.59M |
| Total Equity | -$2.86M | $6.59M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$8.31M | -$1.41M | $14K |
| Depreciation & Amortization | $210K | $105K | $2.5K |
| Change in Receivables | -$84K | $6.3K | -$64K |
| Change in Inventory | -$1.84M | $29K | -$31K |
| **Operating Cash Flow** | -$6.60M | -$1.22M | -$56K |
| Capital Expenditure | -$1.44M | -$75K | -$290 |
| **Free Cash Flow** | -$8.04M | -$1.30M | -$56K |
| **Investing Cash Flow** | -$1.44M | -$2.90M | -$290 |
| Common Stock Issued | $13.20M | $7.55M | -- |
| **Financing Cash Flow** | $10.87M | $7.11M | $114K |
| **Net Change in Cash** | $2.88M | $3.05M | $57K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Gross Margin** | 28.1% | 30.4% | 43.8% |
| **Operating Margin** | -883.3% | -286.5% | -2.8% |
| **Net Profit Margin** | -1392.6% | -276.6% | 3.9% |
| Return on Equity (ROE) | -- | -21.4% | -- |
| Return on Assets (ROA) | -60.3% | -20.6% | -- |
| Current Ratio | 5.88x | 13.18x | -- |
| Quick Ratio | 4.74x | 13.04x | -- |
| Debt to Equity | -- | 0.00x | -- |
| **Revenue Growth (YoY)** | +16.9% | +45.8% | -- |
| Gross Profit Growth (YoY) | +7.8% | +1.2% | -- |
| **Net Income Growth (YoY)** | -- | -10509.7% | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
